Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
Holding MRUS?
Track your performance easily
MRUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.81 - $61.61
Previous Close$50.1
Volume566.57K
Average Volume (3M)608.96K
Market Cap
$3.42B
Enterprise Value$2.64B
Total Cash (Recent Filing)$787.42M
Total Debt (Recent Filing)$11.02M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Oct 30, 2024EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.87
Shares Outstanding68,210,479
10 Day Avg. Volume478,518
30 Day Avg. Volume608,959
Standard Deviation0.18
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.58
Price to Sales (P/S)97.30
Price to Cash Flow (P/CF)151.80
P/FCF Ratio205.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue75.04
Enterprise Value/Gross Profit60.09
Enterprise Value/Ebitda-31.16
Forecast
1Y Price Target
$89.14Price Target Upside80.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Merus News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company expects to dose their first patient in the 1L pivotal trial and will enroll about ~500 patients.
Financial OutlookCash and cash equivalents were reported at $846.4mn, providing a cash runway into 2028, inclusive of all planned trials.
Market PotentialThe only approved targeted treatment towards the EGFR PACC mutant class is afatinib, which has poor tolerability, and so there is a significant unmet clinical need.
Bears Say
Clinical DataBicara's updated Phase 1/1b data for BCA101 seem weaker compared to Merus' MCLA-158 on Overall Response Rate (ORR).
Competitive DisadvantageAmong HPV negative patients, Merus demonstrated a 65% Overall Response Rate (ORR) for MCLA-158 + pembrolizumab compared to 54% for Bicara + pembrolizumab, indicating a significant advantage for Merus.
Safety ConcernsBCA101 showed one grade 3 tracheal hemorrhage at ESMO in 2023, raising concerns about potential bleeding events.
---
Ownership Overview
6.12% Insiders
14.11% Mutual Funds
60.82% Other Institutional Investors
18.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $19.80 and its highest was $61.61 in the past 12 months.
What is Merus NV’s market cap?
Currently, no data Available
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Aug 01, 2024. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.759 by -$0.051.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -$0.87.
How many shares outstanding does Merus NV have?
Merus NV has 68,210,480 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.759. Following the earnings report the stock price went down -0.61%.
Which hedge fund is a major shareholder of Merus NV?
Among the largest hedge funds holding Merus NV’s share is Deerfield Management Company, LP. It holds Merus NV’s shares valued at 163M.
---
Merus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.14 (80.37% Upside)
$89.14 (80.37% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 604.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $270.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.58%
12-Months-Change
Fundamentals
Return on Equity
-33.39%
Trailing 12-Months
Asset Growth
145.37%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
MRUS Stock 12 Month Forecast
Average Price Target
$89.14
▲(80.37% Upside)
Technical Analysis
Best Analysts Covering MRUS
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+53.93%
reiterated a buy rating 2 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +53.93% per trade.
---